share_log

Goldman Sachs Maintains Neutral on Centessa Pharmaceuticals, Raises Price Target to $5

Goldman Sachs Maintains Neutral on Centessa Pharmaceuticals, Raises Price Target to $5

高盛对Centessa Pharmicals保持中立,将目标股价上调至5美元
Benzinga ·  2023/08/15 08:44

Goldman Sachs analyst Salveen Richter maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Neutral and raises the price target from $4.5 to $5.

高盛分析师Salveen Richter维持Centessa PharmPharmticals(纳斯达克:CNTA)的中性,并将目标价从4.5美元上调至5美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发